The functional dysregulation of RRAS2 has been shown to contribute to oncogenesis, as it triggers critical biological processes in cancer cells, including proliferation [84,85], migration, the epithelial–mesenchymal transition [86], and resistance to chemotherapy [87,88]. Here, RRAS2 is linked to cancer.